The breast cancer susceptibility gene (BRCA1) localizes to chromosome 17q.
Mutations within this gene account for approximately 45% of families with high incidence of breast cancer and at least 80% of families with increased incidence of both early-onset breast cancer and ovarian cancer.
A second breast cancer susceptibility gene, BRCA2, located on chromosome 13q12-13, also confers a high incidence of breast cancer, but unlike BRCA1, BRCA2 does not confer a substantially elevated risk of ovarian cancer.
The BRCA2-Associated Factor 35 (BRAF35) protein forms a complex with BRCA2, which associates with condensed chromatin during histone H3 phosphorylation.
BRAF35 expression levels are highest in proliferating tissues and parallel BRCA2 expression patterns.
The structure of BRAF35 includes a kinesin-like coiled coil domain and a nonspecific DNA binding HMG domain.
The chromatin localization of BRAF35 and antibody microinjection studies indicate a role for the BRAF35/BRCA2 complex in cell cycle regulation.
Applications:Suitable for use in Western Blot, Immunohistochemistry, Immunofluorescence, and ELISA.
Other applications not tested.
Recommended Dilution:Western Blot: 1:500-1:2000Immunohistochemistry (paraffin): 1:100-1:300Immunofluorescence: 1:200-1:1000ELISA: 1:20,000Optimal dilutions to be determined by the researcher.
Storage and Stability:May be stored at 4°C for short-term only.
Aliquot to avoid repeated freezing and thawing.
Store at -20°C.
Aliquots are stable for 12 months after receipt.
For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
仕様
Size：30ul
Host：rabbit
Source Antibody：human
Grade：Affinity Purified
Purity：Purified by immunoaffinity chromatography.
Form：Supplied as a liquid in PBS, 0.5% BSA, 0.02% sodium azide, 50% glycerol.
Specificity：Recognizes endogenous levels of human BRAF35.
Isotype：IgG
Calc Applications Abbrev：E IF IHC WB
Calc Crossreactivity：Hu
Immunogen：Synthetic peptide corresponding to aa10-90 of human BRAF35 at N-terminal.
